Outcome | N | OR (95%CrI) | P(%) | τ (95%CrI) | β (95%CrI) | Pβ(%) | |
---|---|---|---|---|---|---|---|
Mortality | Â | Â | Â | Â | Â | Â | |
High dose | 5 | 0.912 (0.313 to 1.253) | 42.0 | 1.00 (0.42 to 1.89) | Â | Â | |
   High dose excluding Schumer [31] | 4 | 1.406 (0.727 to 2.614) | 89.3 | 0.25 (0.01 to 1.40) |  |  | |
Low dose | 9 | 0.796 (0.396 to 1.386) | 20.4 | 0.65 (0.23 to 1.44) | Â | Â | |
   Low dose excluding CSG [32] | 8 | 0.706 (0.371 to 1.096) | 5.8 | 0.39 (0.04 to 1.15) |  |  | |
Corticotrophin responders* | 4 | 0.882 (0.285 to 2.073) | 36.4 | 0.49 (0.02 to 1.78) | Â | Â | |
Corticotrophin non-responders* | 4 | 0.831 (0.334 to 1.971) | 28.0 | 0.43 (0.02 to 1.69) | Â | Â | |
Shock-reversal | Â | Â | Â | Â | Â | Â | |
High dose | 2 | 1.078 (0.227 to 6.311) | 54.9 | 1.39 (0.06 to 1.93) | Â | Â | |
Low dose | 7 | 1.999 (1.069 to 4.55) | 98.2 | 0.57 (0.04 to 1.62) | Â | Â | |
Corticotrophin responders* | 3 | 1.830 (0.499 to 7.845) | 86.7 | 0.87 (0.05 to -1.92) | Â | Â | |
Corticotrophin non-responders* | 3 | 1.845 (0.637 to 7.267) | 91.9 | 0.55 (0.02 to 1.86) | Â | Â | |
Meta-regression (log odds mortality) | Â | Â | Â | Â | Â | Â | |
Average age | High dose | 4 | 0.777 (0.285 to 2.426) | 27.3 | 0.72 (0.04 to 1.87) | 0.60 (-0.23 to 1.51) | 94.52 |
 | Excl Schumer [31] | 3 | 1.390 (0.399 to 4.872) | 77.0 | 0.66 (0.03 to 1.90) | 0.10 (-1.57 to 1.74) | 58.05 |
 | Low dose | 6 | 0.658 (0.334 to 1.223) | 7.6 | 0.36 (0.02 to 1.51) | 0.05 (-0.10 to 0.18) | 80.53 |
Underlying risk | High dose | 5 | 0.943 (0.292 to 3.049) | 45.4 | 1.14 (0.46 to 1.49) | 0.23 (-1.71 to 2.58) | 60.98 |
 | Excl Schumer [31] | 4 | 1.372 (0.596 to 3.249) | 82.9 | 0.38 (0.01 to 1.74) | -0.09 (-1.31 to 1.42) | 41.47 |
 | Low dose | 9 | 0.752 (0.389 to 1.291) | 14.5 | 0.57 (0.17 to 1.37) | -0.49 (-1.14 to 0.27) | 7.80 |
 | Excl CSG [32] | 8 | 0.676 (0.347 to 1.076) | 4.9 | 0.40 (0.03 to 1.23) | -0.28 (-0.88 to 0.50) | 19.08 |
Odds of the following complications (corticosteroids versus control) | Â | Â | Â | Â | Â | Â | |
Superinfection | High dose | 4 | 1.127 (0.364 to 3.924) | 62.2 | 0.55 (0.02 to 2.85) | Â | Â |
 | Low dose | 6 | 0.955 (0.388 to 1.749) | 43.6 | 0.46 (0.03 to 1.62) |  |  |
GI bleeding | High dose | 3 | 0.824 (0.167 to 3.186) | 37.3 | 0.74 (0.03 to 1.90) | Â | Â |
 | Low dose | 5 | 1.103 (0.379 to 3.031) | 59.6 | 0.58 (0.02 to 1.84) |  |  |
Hyperglycemia | High dose | 3 | 1.012 (0.244 to 4.266) | 50.8 | 0.64 (0.03 to 1.88) | Â | Â |
 | Low dose | 3 | 1.430 (0.155 to 3.985) | 57.4 | 0.87 (0.05 to 1.93) |  |  |